SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings ($OCTO) is trending due to a massive surge, reportedly fueled by news of a significant treasury strategy. The community is discussing the potential for a short squeeze and comparing it to other high-flying stocks, while also questioning the long-term sustainability given news of share dilution.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

SNTG is trending due to speculation of a potential short squeeze, drawing comparisons to other recently volatile low-float stocks. Community chatter highlights the stock's low float and potential for significant upward movement, with some traders actively discussing strategies to capitalize on anticipated price swings. The stock is also being mentioned alongside other Chinese and Hong Kong-based stocks experiencing similar momentum.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

ASST is trending as community members discuss an upcoming merger and its potential impact, drawing comparisons to the recent surge in $OCTO. Key talking points revolve around the shareholder vote, potential short squeeze dynamics given high short interest, and speculation about the effect of a bitcoin treasury strategy post-merger. Some traders are also eyeing technical indicators and dark pool activity for clues about the stock's next move.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as the community debates its future, focusing on the approaching expiration of Carvana's warrants and the potential implications.  Discussions revolve around the stock's valuation, profitability, and potential catalysts, with some expressing frustration over management's communication. Bulls highlight the company's partnerships and growth potential, while bears point to ongoing losses and dilution concerns.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is trending downwards, with community members expressing frustration over the stock's performance and concerns about the company's leadership and business strategy. Some investors are pointing to potentially overpriced menu items and increased competition in the fast-casual dining sector as contributing factors, while others are looking for a near-term bottom.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar ($GSAT) is trending as investors anticipate potential news from an upcoming Apple event, possibly related to their existing partnership for satellite services. Community members are speculating about the implications of SpaceX's recent spectrum acquisition and its potential impact on Globalstar's valuation, with some suggesting a bidding war may ensue. Bullish sentiment is fueled by the company's spectrum assets and potential for expansion in the satellite communications sector.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending due to a reported takeover offer from Nestle, which has ignited significant community discussion about the potential deal's implications. The community is actively analyzing the offer's structure, potential milestone payments, and the strategic rationale behind a Nestle acquisition. With a presentation at the H.C. Wainwright conference, shareholders are hoping for clarity on the company's future direction amidst buyout speculation.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending after reporting record Q2 revenue and raising its full-year guidance, sparking optimism about the company's path to profitability. The community is discussing the potential for a continued rally, driven by strong backlog and government contracts, with some speculating about a possible revaluation. A Seeking Alpha article notes the valuation has outrun fundamentals, while others highlight the company as a unique AI space stock.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending due to a Barron's article sparking investor interest, with the community discussing potential pullbacks and profit-taking opportunities as the stock approaches the $50 resistance level. The company's focus on Agentic AI and curated data is also a key talking point, as investors assess its potential in the evolving AI landscape. Despite some profit-taking, bullish sentiment remains strong, fueled by increasing institutional investment and anticipation of future growth.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the showcase of their solid-state batteries in a Ducati motorcycle, marking a significant step towards real-world application of the technology. The community is discussing the potential for faster charging, higher energy density, and the implications of Volkswagen's backing. Many believe this demonstration validates the technology and could lead to further partnerships and increased production.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) delivered earnings and revenue surprises of +66.67% and +10.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

Xeris Biopharma - Possibly the best Pharma Stock

Summary Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28. The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. Barchart indicators show 100% technical buy signals, a 95.32% gain in the...

Shares of Xeris Biopharma Inc. surged more than 9.5% on Thursday, reaching their highest level since June 2021, driven by a better-than-expected revenue forecast for 2025 that fueled investor optimism.&nbsp;The rally came despite a slightly wider-than-expected quarterly loss, with retail sentiment increasingly bullish following the earnings release.Xeris reported an adjusted fourth-quarter loss of $0.03 per share, narrowly missing Wall Street expectations of a $0.02 loss.&nbsp;However, revenue for the period was $60.01 million, exceeding the consensus estimate of $58.54 million.&nbsp;The company's full-year guidance emerged as the key driver of market enthusiasm. Xeris expects 2025 revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.CEO John Shannon described 2024 as an "exceptional" year, as revenue surpassed $203 million to a record high.&nbsp;CFO Steven Pieper said record quarterly revenue of more than $60 million in&nbsp;Q4 contributed to a positive cash flow of $2 million and adjusted&nbsp;earnings before interest, taxes, depreciation, and amortization (EBITDA) of over $8 million.&nbsp;He added that the 2025 revenue outlook represents more than 30% growth at the midpoint.Xeris currently markets three key products: Recorlev for endogenous Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis.&nbsp;It is also advancing a pipeline of development programs, led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, alongside several early-stage programs leveraging its technology platforms.On Stocktwits, sentiment for Xeris turned 'extremely bullish' (89/100) and reached its highest score in a year, with message volume surging by 780% in the 24 hours to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/XERS_sentiment_and_message_volume_as_of_March_6_14ecb19082.png" alt="XERS sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>XERS sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user noted that the stock's long period of stagnation, "like 40 qtrs in the desert," had finally given way to momentum.&nbsp;<stembedurl>https://stocktwits.com/NobVega/message/607012972</stembedurl>Another speculated about the possibility of a buyout, suggesting that Xeris could attract an acquisition offer by the end of the year.<stembedurl>https://stocktwits.com/Finwizard61/message/607030000</stembedurl>Short interest in Xeris last stood at 6.9%, according to Koyfin data. The company's stock, which was falling after-hours on Thursday, has gained nearly 22% since the start of the year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

Equity

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.


Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris to Participate in Upcoming Investor Conferences

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients lives by developing and commercializing innovative products across a range...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XERS News

XERS Xeris Biopharma Holdings Inc